Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

The Effect of Glucomannan Powder on Improving Gut Microbiota.

NCT07231003 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2025-08-28
Last updated
2025-11-17

Condition(s) studied

Dysbiosis

Investigational drug(s) / intervention(s)

GlucomannanPlacebo

Glucomannan: 2 packs of glucomannan, 2 grams per pack

Placebo: 2 packs of corn starch, 2 grams per pack

Study summary

The object of this study is evaluating the effects of the Glucommanan on the healthy human subjects who are. In this trial, at most 30 healthy subjects whose ages are 20\~65 years old (15 for placebo and 15 for intervention)will be included. The total experiment will be 9 weeks and the intervention period will be 6 weeks, within which, at week 0, 6, and 7, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), aspartate aminotransferase (AST, also known as GOT), alanine aminotransferase (ALT, also known as GPT), blood urea nitrogen (BUN), serum creatinine (Cr), fasting blood glucose (Glucose, AC) and adiponectin would be measured. Feces samples and anthropometric data will also be acquired. The results will be analyzed according to the methods published by the Ministry of Health and Welfare of Taiwan Food and Drug Administration.

Eligibility

Sex
ALL
Min age
20 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: \- Both genders, aged between 20 and 65 years. No history of gastrointestinal disorders or other significant health issues. Overall good health. Exclusion Criteria: \- Participants who have taken antibiotics or any medications/supplements that could affect the gut microbiota within 1 week prior to the experiment or during the study. Pregnant or breastfeeding women. Smokers or individuals with excessive alcohol consumption. Chronic disease medication usage for less than 3 months. Postmenopausal women on hormone replacement therapy. Individuals with acute illnesses such as a cold.

Primary outcome measure(s)

  • gut microbiota — Week(0) (Baseline), Wk(6),Wk7
    Evaluation of Gut Microbiota by Analysis of Four Indicator Strains and 16S rRNA Sequencing Using Fecal Samples

Trial sites (1)

FacilityCityRegionStatus
Taipei Medical University Taipei Taiwan
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07231003 on ClinicalTrials.gov ↗ ← All trials in Taiwan